Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL-Reference-Cited by-同舟云学术

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Published:2020-01-30 Issue:5 Volume:135 Page:387-391
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Pan Jing¹^ORCID,Zuo Shiyu²,Deng Biping³,Xu Xiuwen⁴,Li Chuo²,Zheng Qinlong⁴,Ling Zhuojun⁵,Song Weiliang⁵,Xu Jinlong⁵,Duan Jiajia⁵,Wang Zelin⁵,Yu Xinjian⁴,Chang Alex H.⁶,Feng Xiaoming²⁷,Tong Chunrong⁵

Affiliation:

1. State Key Laboratory of Experimental Hematology, Beijing Boren Hospital, Beijing, China;

2. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China;

3. Cytology Laboratory,

4. Medical Laboratory, and

5. Department of Hematology, Beijing Boren Hospital, Beijing, China;

6. Clinical Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; and

7. Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, China

Abstract

Pan and colleagues report one of the first prospective evaluations of planned sequential chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and then CD22 in a phase 1 trial, indicating acceptable toxicity and encouraging durable efficacy in pediatric patients with relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL).

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/5/387/1632887/bloodbld2019003293.pdf

Reference17 articles.

1. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study;Sun;Leukemia,2018

2. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients;Pan;Leukemia,2017

3. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy;Fry;Nat Med,2018

4. Chimeric antigen receptor T cells for sustained remissions in leukemia;Maude;N Engl J Med,2014

5. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse;Kenderian;Biol Blood Marrow Transplant,2017

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

2. Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia;Blood Reviews;2024-07

3. Programmable cancer treatments: Engineering biology approaches for living cures;Engineering Biology;2024-05-31

4. Recent Advances and Challenges in Cancer Treatment with Car T Cell Therapy: A Novel Anti-cancer Strategy;BioNanoScience;2024-04-09

5. Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells;International Journal of Nanomedicine;2024-03